Synthetic core 2-like branched structures containing galnac-lewisx and neu5ac.alpha.2-3gal.beta.1-3galnac sequences as novel ligands for selectins
CA 2249879 A1 · Owner: Matta, Khushi L. · Inventors: Jain, Rakesh K.; Matta, Khushi L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds which bind to selectin receptors and thus may modulate the course of inflammation, cancer and related processes by intervening with cell-cell adhesion events. Further, such compounds can be used for identification and analysis of such receptors. In this regard the invention is directed to compounds of formula (I). wherein R1 is independently H alkyl aryl, an aryl alkyl, alkenyl or one or moreadditional saccharide residues; R2 = H or OH provided that when R2 is H R3 is OH;, R3 = H or OH provided that when R3 is H R2 is OH;, X = H, SO3- or PO4-;, Y is independently H OH, OR4 or NHCOR4, wherein R4 is alkyl and, Z is an organic acid residue. .alpha.-L-Fucose residue (a) can be …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 8, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 8, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 8, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.